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The insulin and insulin-like growthfactor 1receptors activate overlapping signalling pathwaysthat
are critical for growth, metabolism, survival and longevity. Their mechanism of ligand binding and
activation displays complex allosteric properties, which no mathematical model has been able to
account for. Modelling these receptors’ binding and activation in terms of interactions between the
molecular components is problematical due to many unknown biochemical and structural details.
Moreover, substantial combinatorial complexity originating from multivalent ligand binding
further complicates the problem. On the basis of the available structural and biochemical
information, we develop a physically plausible model of the receptor binding and activation, which
is based on the concept of a harmonic oscillator. Modelling a network of interactions among all
possible receptor intermediaries arising in the context of the model (35, for the insulin receptor)
accuratelyreproducesfortheﬁrsttimeallthekineticpropertiesofthereceptor,andprovidesunique
and robust estimates of the kinetic parameters. The harmonic oscillator model may be adaptable for
many other dimeric/dimerizing receptor tyrosine kinases, cytokine receptors and G-protein-
coupled receptors where ligand crosslinking occurs.
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Introduction
Insulin and insulin-like growth factors (IGF) 1 and 2 have
similar structures and exert their action by activating two
closely related receptor tyrosine kinases—the insulin receptor
and the IGF1 type I receptor (IGF1 receptor), which share
largely overlapping signalling pathways (Adams et al, 2000;
De Meyts and Whittaker, 2002; De Meyts, 2004; Denley et al,
2005). Despite this similarity, the two hormones produce
different responses: mostly metabolic for insulin and mito-
genic for IGF1 (Kim and Accili, 2002). Dysregulation of their
signalling may lead to two different life-threatening diseases:
type II diabetes and cancer, which areamong the largest global
health challenges in the world. So far, there is poor under-
standing of how these hormones produce such different
biological effects using similar signalling networks (Kim and
Accili, 2002). It has become clear that a systems biology
approachisrequiredtounderstandthecombinatorialnatureof
signalling speciﬁcity (Shymko et al, 1997; Kholodenko, 2007).
Insulin analogues with altered kinetic properties show
enhanced mitogenic potencies, although they bind to the
sameinsulin receptor; theyalsocross-react toavariableextent
with the IGF-I receptor (Shymko et al, 1997; Kurtzhals et al,
2000). Differences in kinetics of ligand binding and receptor
activation by the insulin and IGF1 receptors may be one of the
factors determining their speciﬁcity (Shymko et al, 1997).
The two receptors’ mechanism of ligand binding and activa-
tion displays complex allosteric properties (i.e. negative
cooperativity and ligand dependence of the receptor dissocia-
tion rate),which no mathematicalmodel has been able to fully
account for (Jeffrey, 1982; Kohanski and Lane, 1983; Ham-
mond et al, 1997; Wanant and Quon, 2000; Sedaghat et al,
2002). Thus, the development of a reliable mathematical
model describing the two receptors’ binding kinetics and
activation is a critical ﬁrst step in a systems biology approach
to understand the function and speciﬁcity of these receptors.
The insulin and IGF1 receptors exist in the membrane as
pre-formed covalent dimers of two identical moieties. Their
extracellular domains comprise two leucine-rich repeat-con-
taining large domains (L1 and L2) separated by a cystein-rich
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www.molecularsystemsbiology.com(CR) domain, followed by three ﬁbronectin type III (Fn1–3)
domains (Adams et al, 2000; De Meyts and Whittaker, 2002;
De Meyts, 2004). A crystal structure of this extracellular
(unliganded) insulin receptor dimer has recently been solved
(McKern et al, 2006; Lawrence et al, 2007; Ward et al, 2007,
2008).Theintracellularportionofthetworeceptorsconsistsof
a kinase domain ﬂanked by regulatory regions (Hubbard and
Miller, 2007).
The insulin and IGF1 receptors exhibit complex binding
properties. The Scatchard plots for both receptors are concave
up, indicating the presence of high- and low-afﬁnity binding
sites and/or negative cooperativity (De Meyts et al, 1973,
1976; De Meyts, 1994). The receptors bind only one ligand
moleculewith highafﬁnityandatleast anotheronewith lower
afﬁnity. The ligand dissociation rate is dependent on its
concentration (De Meyts et al, 1973, 1976; De Meyts, 1994).
Furthermore, this dependence is bell-shaped for the insulin
receptor, whereas for the IGF1 receptor, it is sigmoid
(Christoffersen et al, 1994). When the insulin receptor is in a
monomeric form, its afﬁnity is reduced 30-fold, the Scatchard
plot becomes linear and the dissociation rate of the ligand
becomes independent of its concentration (De Meyts, 1994,
2004; De Meyts and Whittaker, 2002).
Insulin has two receptor-binding surfaces on the ‘opposite’
sides of the molecule. The ﬁrst ‘classical’ binding surface, also
involved in insulin dimerization, was deﬁned in the early
1970s (Pullen et al, 1976; De Meyts et al, 1978), and later
validated by alanine-scanning mutagenesis (Kristensen et al,
1997), whereas the second surface, also involved in insulin
hexamerization, was mapped by alanine-scanning mutagen-
esis more recently (De Meyts, 2004; Gauguin et al, 2008). The
dimerization surface interacts with a site located in the L1
module of the insulin receptor, as well as a 12 amino-acid
peptide from the insert in Fn2, which combine to form ‘site 1’
(Wedekind et al, 1989; Kurose et al, 1994; Williams et al, 1995;
Mynarcik et al, 1996; De Meyts and Whittaker, 2002;
Kristensen et al, 2002; Huang et al, 2004), whereas the
hexamerization surface interacts with a site consisting of
residues located in the C-terminal portion of L2 and in the Fn1
and Fn2 modules (site 2) (Fabry et al, 1992; De Meyts and
Whittaker, 2002; Hao et al, 2006; Benyoucef et al, 2007;
Whittakeret al,2008).Scha ¨ffer(1994)suggested thatthehigh-
afﬁnity binding could result from insulin crosslinking site 1 of
one receptor half and site 2 of the other half of the receptor
dimer, thus leaving the other two sites free for interaction with
theligand.However,thismodelhaddifﬁcultyinexplainingthe
ligand dependence of the ligand dissociation rate. De Meyts
(1994) suggested that this problem could be solved by
assuming that the four sites of the receptor dimer are arranged
in a symmetrical antiparallel way, a postulate that was
supported by the recent structure determination of the insulin
receptor extracellular domain (McKern et al, 2006). Despite its
seeming simplicity, this model turned out to be notoriously
difﬁcult for a quantitative analysis and some researchers even
concluded that it did not explain the ligand dependence of the
dissociation rate (Hammond et al, 1997). The problem is that
the qualitative crosslinking models suggested by Scha ¨ffer
(1994) and De Meyts (1994) are not detailed enough from a
biochemical and structural viewpoint for mathematical
modelling (especially concerning the precise mechanism that
leads to receptor crosslinking). The modelling problem is
further aggravated by combinatorial complexity arising from
multivalent ligand binding to the receptor in multiple possible
conformations. We have now solved this problem.
Here, we present the ﬁrst mathematical model that
accurately reproduces all the kinetic properties of the insulin
receptor such as negative cooperativity and the bell-shaped
ligand dependence of the receptor dissociation rate. On the
basis of the available structural information, we develop a
physically plausible model of the receptor activation, which is
based on the concept of a harmonic oscillator. We justify
thermodynamically that the symmetrically arranged subunits
of the insulin receptor dimer experience harmonic oscillatory
movements. Analysis of the behaviour of an ensemble of such
harmonic oscillators in thermal equilibrium with the sur-
rounding milieu allows to model the receptor activation in a
simple way and to substantially reduce the combinatorial
complexity. This model is the ﬁrst one that gives a description
of the insulin receptor binding and activation mechanism in
terms of interactions between the molecular components and
fully takes into account the combinatorial binding complexity
(employing 35 insulin receptor intermediaries). Fitting of the
model to experimental data provides unique and robust
estimatesofthekineticparameters.Withasmallmodiﬁcation,
the model can also be used for the IGF1 receptor. Furthermore,
the harmonic oscillator model may be adaptable for many
otherdimericordimerizingreceptortyrosinekinases,cytokine
receptors and G-protein-coupled receptors where ligand cross-
linking occurs (De Meyts, 2008).
Theory and results
Our goal is to develop a physically plausible mathematical
model of the insulin receptor-binding and activation mechan-
ism in terms of interactions between the molecular compo-
nents. This, however, requires the knowledge of the precise
mechanism of interaction between the components involved,
for which some biochemical and structural details are still
missing. Thus, some assumptions are unavoidable. All of the
assumptions made in this article are justiﬁed from the
physicochemical point of view and are therefore physically
plausible.
Binding of insulin to the inactive conformation
of the insulin receptor
The structure of the insulin receptor dimer in the unliganded
conformation displaysa symmetrical antiparallel arrangement
of the receptor’s two binding sites for insulin (McKern et al,
2006) (see Figure 1A and C). From nowon, a pairof sites 1 and
2 from the different receptor subunits will be referred to as a
‘crosslink’.Thestructureshowsthatthedistancebetweensites
1 and 2 (within the same crosslink) is rather small (see
Figure 1B), indicating that if an insulin molecule binds to
either of these sites, there is not enough room for binding of a
second insulin molecule. Thus, it is reasonable to assume that
only one insulin molecule can bind to the same crosslink
(either to site 1 or 2), when the receptordimer is in the inactive
conformation. Mathematical modelling of insulin binding to
Insulin receptor as a harmonic oscillator
VV Kiselyov et al
2 Molecular Systems Biology 2009 & 2009 EMBO and Macmillan Publishers Limitedthe inactive conformation of the insulin receptor is straightfor-
ward and requires only four parameters: association rate
constants for sites 1 and 2 (designated a1 and a2, respectively)
and dissociation rate constants for sites 1 and 2 (designated d1
and d2, respectively). The four sites will from now on be
designated as sites 1, 2, 3 and 4, where sites 3 and 4 are
identical to sites 1 and 2, respectively, but from a different
crosslink (see Figure 2A). Binding of insulin to the inactive
conformation of the insulin receptor gives rise to nine
intermediaries, designated r0, r1, r2, r3, r4, r13, r14, r23 and r24
(where indices i and j in ri and rij designate the number of the
site to which insulin is bound) (see Figure 2A).
Conformational change in the insulin receptor
upon insulin binding
Currently, the precise mechanism of the insulin receptor
crosslinking reaction required for mathematical modelling is
not known. Therefore, we will analyse the available structural
information from a physicochemical point of view to derive a
plausible model.
In the absence of insulin, the insulin receptor adopts an
inactive, symmetrical conformation (McKern et al, 2006) (see
Figure 1A and C). Binding of insulin to both sites of a crosslink
is thought to produce a conformational change in the insulin
receptor, which is necessary for its activation. The crystal
structure of the insulin receptor (McKern et al, 2006) is
consistent with an assumption (as previously suggested by De
Meyts, 1994) that this conformational change is produced bya
tilt of the receptor subunits, leading to a movement of sites 1
and 2 towards each other and to a corresponding movement of
sites from the second crosslink away from each other. This
structural rearrangement is schematically shown in Figure 1D
and E, in which the symmetrically arranged subunits of the
receptor dimer are approximated by rigid bodies. Obviously,
the tilted (activated) conformation has higher free energy than
the symmetrical, inactive conformation (otherwise there
would be a substantial receptor activation in the absence of
insulin), probably due to slight distortion of bond angles and
lengths. Thus, it is reasonable to assume that receptor
molecules can exist in both inactive and active conformations,
with equilibrium being strongly shifted towards the inactive
(energetically more favourable) conformation in the absence
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Figure 1 Insulin receptor structure.In allof the panels, the individual monomers of the insulinreceptor dimerare coloured ingreen andblue, respectively, and location
of the binding sites is shown approximately, as the residues involved in binding to insulin are not known precisely. (A) Crystal structure of the ecto-domain of the insulin
receptordimer(PDBcode:2DTG).Labellingofthemodulesisshownonlyfortheblue-colouredmonomer.(B)Halfoftheinsulinreceptordimerisshown.Theplacement
of insulin in the binding cavity is shown approximately. (C) A view of the insulin receptor dimer (shown in (A)) as seen from the ‘top’. (D) Simpliﬁed representation of the
insulin receptor dimer, in which the insulin-binding subunits are represented as rigid bodies. (E) Crosslinked (tilted) conformations of the rigid-body representation of the
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simultaneously to sites 1 and 2 of the same crosslink when the
receptor molecules are in the tilted conformation and thus
stabilize the active conformation.
Insulin receptor as a harmonic oscillator:
a physically plausible model of the receptor
conformational change
As discussed above, the tilted (active) conformation of the
insulinreceptorhashigherfreeenergycomparedwiththenon-
tilted (inactive) conformation. It is reasonable to assume that
largertiltanglesresultinlargerfreeenergyvalues,andthatthe
insulinreceptorfreeenergyhasalocalminimumatthezerotilt
angle. Therefore, in a sufﬁciently small vicinity around the
zero tilt angle, the system behaviour can be approximated by
harmonic oscillations (Bloch, 1997). Let us consider the
energy of the insulin receptor oscillations when the insulin
receptor is in thermal equilibrium with the buffer. Then, the
receptor molecules will have various energies (received from
accidental collisions with the buffer molecules), and their
distribution will be according to the Maxwell–Boltzmann
formula (Bloch, 1997), which for a one-dimensional harmonic
oscillator takes the form:
dP
dE
¼
1
kT
e E=kT ðFigure3AÞ
where P, E, k and T stand for probability, energy, Boltzmann
constant and absolute temperature, respectively. As appears
fromFigure3A,themostlikelystateofthereceptoristhatwith
the zero energy of oscillations (corresponding to the zero tilt
angle, or an inactive conformation), with the probability
density of ﬁnding receptor molecules with higher energies
decreasing exponentially as a function of energy. The
Maxwell–Boltzmann distribution implies that a small fraction
of receptor molecules will have sufﬁcient energy to reach the
tilt angle of the activated receptor in the absence of insulin
(Figure 3A). This fraction can be easily derived from the
Maxwell–Boltzmann distribution if the activation energy
(designated Eact), corresponding to the tilt angle of the
activated receptor, is known:
Fraction ¼
Z 1
Eact
1
kT
e E=kT dE
To estimate the fraction of the activated insulin receptor
molecules in the absence of insulin, we note that the insulin
receptor basal autophosphorylation rate is increased 10- to
20-fold in the presence of insulin (Flores-Riveros et al, 1989;
Kohanski, 1993). It is reasonable to assume that the autopho-
sphorylationrateisproportionaltothefractionoftheactivated
receptor molecules and that the basal rate is proportional to
this fraction in the absence of insulin. Thus, around 5–10% of
the receptor molecules are estimated to be activated in the
absence of insulin. From this, the activation energy of the
insulin receptor can be roughly estimated from the above
equation as 5–8kJmol
 1. Interestingly, the conformational
change of the EGF receptor also requires about 4–8kJmol
 1
(Ozcan et al, 2006), indicating that the above estimation is
reasonable.
It should be pointed out that large-scale collective motions
in a macromolecule are determined mostly by the macro-
molecule’s global topology and are insensitive to structural
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be rigid bodies connected by elastic springs provide a good
description of the allosteric dynamics (for review, see Bahar
and Rader, 2005). From this perspective, the rigid body model
of the symmetrical insulin receptor dimer with elastic springs
attached as shown in Figure 3B (compare it with Figure 1C) is
expectedtoprovideadecentdescriptionoftheinsulinreceptor
dynamics. Indeed, such a model will be capable of the
conformational changes shown in Figure 1E and the move-
mentofitssubunitswillbedescribedbyharmonicoscillations.
In the following, this rigid body model of the insulin receptor
dimer will serve as a basis for modelling of the crosslinking
reaction.
Deﬁnition of the crosslinking constant
Let us consider the behaviour of the r0 intermediary in the
absence of insulin. The harmonic oscillator model implies that
in the absence of insulin there are no intermediaries with a
certain stable tilt angle, although the zero tilt angle is most
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collisions of the solvent molecules with the receptor subunits)
until an activation state is achieved, which will only be
transient because the oscillation will continue its swing in the
reverse direction and quickly lose its energy due to interaction
with the solvent. The r0 receptor molecules with energy of
oscillations less than the energy of activation, designated *r0
(and therefore in the inactive state), will reach an active state,
*r0, on average after a certain time period, t. Then, transition
from *r0 to
*r0 can be modelled as a ﬁrst-order reaction with
a rate constant equal to 1/t, designated from now on as the
crosslinking constant, kcr (see Figure 3A). As approximately
5% of receptor molecules are in the active state (see above),
the transition from
*r0 to *r0 can be modelled as a ﬁrst-order
reaction with a rate constant equal to 19 kcr (Figure 3A).
Activation of the insulin receptor according to the
harmonic oscillator model
Let us consider the activation of an inactive r1 intermediary
(activation of all other inactive intermediaries can be
considered in a similar way). The most likely state of this
intermediary(withzeroenergyofoscillations)isdesignatedas
or1 and those states with energy of oscillations less than
activation energy (including or1)—as *r1 (see Figure 3B),
which represent the r1 receptor species in an inactive state.
Subunits of the *r1 intermediaries will be experiencingrandom
forces acting on them (shown by vectors F in Figure 3B) due to
thermal motion of the solvent molecules. These forces will be
varying in magnitude, direction and act for various periods of
time. When these forces act synergistically for a sufﬁcient
period of time, an active state will be achieved, which (as
mentioned above) will happen on average after a time period,
t, and transition to the active state, designated as
*r1
þ (see
Figure 3B), from the inactive can be modelled as a ﬁrst-order
reaction with a rate constant, kcr, equal to 1/t. As in the active
state, the distance between insulin and site 2 is zero, the local
concentration of insulin in the vicinity of site 2 becomes
‘inﬁnite’, which means that the subsequent binding of insulin
to site 2, and thus formation of r1 2, is ‘instant’ (see
Figure 3B). To discriminate between
*r1
þ and r1 2, the
*r1
þ
intermediary is shown in Figure 3B with a small distance
between insulin and site 2, which can also be interpreted as a
snapshot of
*r1
þ just beforeit reaches the activestate. The r1 2
intermediary will exist until one of the sites of the crosslink
dissociates. Let us assume that it is site 2 that dissociates. This
leads to the formation of
*r1
  (see Figure3B). Similar to the
*r1
þ
intermediary,
*r1
 isshownwithasmalldistancebetweensite2
and insulin, which can be interpreted as a snapshot of
*r1
  just
after dissociation of site 2. There is an important difference
between
*r1
 and
*r1
þ.Thetwointermediarieshaveidenticaltilt
angles, the same kinetic and potential energies of oscillations.
But in
*r1
þ the crosslinking subunits move towards each other
(see Figure 3B, the direction of movement is indicated by
vectors t), meaning that r1 2 will be formed in an instant,
whereasin
*r1
 thecrosslinkingsubunitsmoveawayfromeach
other (see Figure 3B), meaning that r1 2 will not be formed
because as soon as
*r1
  loses a small fraction of its energy due
to interaction with the solvent, its energy becomes less than
energy of activation, and thus by deﬁnition it becomes *r1.
Thus, transition from
*r1
  to *r1 (see Figure 3B) can be
considered as almost instant.
Reaction scheme for the insulin receptor activation
in the harmonic oscillator model
As can be seen from Figure 3B, formation of r1 2 from *r1 is
rate limited by the ﬁrst reaction (*r1-
*r1
þ) with a rate
constant, kcr, and dissociation of r1 2 into *r1 is also rate
limited by the ﬁrst reaction (r1 2-
*r1
 ), which is a rate
constant fordissociation ofsite 2 in r1 2, designated d2
0
. Asthe
concentration of *r1 is practically the same as that of r1
(approximately 95% of that), the activation scheme shown in
Figure 3B can be reduced to a very simple scheme: r1$r1 2
(seeFigure4A),wheretheforwardreaction hasarateconstant
equal to kcr, and the reverse—d2
0. By analogy, formation of
r1 2 from r2 is described by a similar scheme: r2$r1 2 (see
Figure 4A), where the rate constant of the reverse reaction
(dissociation of site 1 in r1 2) is designated as d1
0.
Binding of insulin to the crosslinked insulin
receptor intermediaries
The crosslinking reaction leads to the formation of another six
crosslinked/activated intermediaries, designated r1 2, r3 4,
r1 23, r1 24, r13 4 and r23 4 (where sign ‘ ’i n1  2 (or
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Figure 4 Reaction scheme for the insulin receptor binding. (A) Scheme of the
crosslinking reaction. (B) Simpliﬁed scheme of the insulin receptor kinetic
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black dot.
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4)fromtheinactiveintermediaries (r1,r2,r3,r4,r13, r14,r23 and
r24) (Figure 2B). Everything described so far for the insulin
receptor can also be applied to the IGF1 receptor. Because of
the tilt of the insulin receptor subunits in r1 2, the distance
between sites 3 and 4 is increased (compared with the inactive
conformation) (see Figure 1D and E), indicating that the
insulin receptor may now bind two more insulin molecules (to
sites 3 and 4), in contrast to inactive r1 (which can only bind
one more insulin molecule, either to site 3 or 4). Thus, we
make an assumption that the insulin receptor can bind up to
three insulin molecules, only when it is in the active state. As
will be shown later, this assumption leads to a bell-shaped
ligand dependence of the dissociation rate. Without this
assumption, this dependence becomes sigmoid. Thus, for the
IGF1 receptor it will be assumed that a third IGF1 molecule
cannot bind to the receptor, which is reasonable because IGF1
is larger in size compared with insulin. In addition, the
geometry of the binding sites in the IGF1 receptor is somewhat
different from that of the insulin receptor, which could also be
the reason why the third IGF1 molecule cannot bind to the
receptor. Site 1 is more extensive in the IGF1 receptor complex
becauseinadditiontothe‘classical’bindingsurfacebindingto
L1, the C-peptide of IGF1 (absent in insulin) binds to the CR
region (Keyhanfar et al, 2007). Other structural differences
between site 1 of the insulin and IGF1 receptors in the L1
domain are reviewed in Lou et al (2006). Binding of the third
insulin molecule to the insulin receptor leads to two more
intermediaries: r1 234 and r123 4 (Figure 2C). The r1 2
intermediary will exist until one of the sites of the crosslink
dissociates, leading to either r1 (dissociation of site 2) or r2
(dissociation of site 1), with the corresponding dissociation
rate constants, d2
0 for site 2, and d1
0 for site 1. It is tempting to
assume that d1
0¼d1 and d2
0¼d2. This is not necessarily so. For
dissociation of insulin from r1 to take place, some energy
should be supplied to r1 for breaking the binding of insulin
from site 1 (the energy comes from random collisions with the
solvent molecules). However, it is obvious that slightly less
energy is required when the insulin receptor is in r1 2
conformation, because this conformation is ‘strained’ (in
contrast to the ‘relaxed’ r1 conformation), and the pull of the
‘strained’ receptor subunits contributes to breaking the
binding of insulin from site 1. Thus, d1
0 is expected to be
larger than d1. Using the same reasoning, d2
0 is expected to be
larger than d2. Because the energy of the ‘strained’ r1 2
conformationisexpectedtoberathersmall(7.5kJmol
 1),one
may expect that d1
0 (d2
0) is not much largerthan d1 (d2). But as
it is not possible to predict precisely how much larger, two
caseswillbeconsidered.Intheﬁrst,itwillbeassumedthatthe
increase is insigniﬁcant, or d1
0¼d1 and d2
0¼d2. In the second
case, there will be no such assumption.
Effect of insulin dimerization
Insulin dimerizes in solution with a Kd value of approximately
7mM (Pekarand Frank, 1972). After insulin dimerization, only
the hexamerization site is available for interaction of the
insulin dimer with sites 2 and 4. It is not known whether the
insulin dimercan bind to the receptor. However, if we makean
assumptionthatthedimercanbindtothereceptorwhenitisin
the active state, then simulations show that this binding is
negligible. Thus, we can use our modelling results as evidence
that the dimer does not bind to the receptor. However, as it is
not possible to predict this result in advance, binding of the
dimer is considered in the model. The insulin dimer could
potentiallybindonlytosite2ofr3 4andsite4ofr1 2,leading
to another two intermediaries r2d3 4 and r1 24d(Figure 2C).
Modelling the insulin receptor binding kinetics
Binding ofinsulintotheinsulin receptorleadstotheformation
of 19 intermediaries (see Figure 2) through a network of 72
individual interactions (if one counts all possible interactions
betweenthese19intermediaries).Theessentialfeaturesofthis
network (with 12 intermediaries and 32 interactions) are
demonstrated in Figure 4B. The complete network is shown in
Supplementary Figure S3 and the corresponding differential
equations in Supplementary Figure S6. It should be noted that
the model does not ‘allow’ direct dissociation of the cross-
linking insulin (binding sites 1 and 2 simultaneously) from
r1 234untiloneoftheinsulinmoleculedissociatesfromsites3
or 4. This is a consequence of the assumption that the third
molecule can bind only when the receptor is in the active state
(see above). This means that as long as the third molecule is
bound, the receptor is in the active state (if not, the third
molecule would be bound to the receptor in the inactive state,
contradicting the assumption). If one of the receptor’s sites
binding to the crosslinking insulin dissociates, the active
conformation will still be maintained (as the third insulin
molecule is bound). However, as the local concentration of the
crosslinking insulin in the vicinity of the dissociated site is
‘inﬁnite’ (because the active state is still maintained), the
crosslinking insulin is expected to ‘instantly’ rebind. Another
reason is that the crosslinking insulin could be entrapped
between the receptor subunits when the receptor is in the
active state (see Figure 1B), and as long as the active state is
maintained,insulinmaynotbeabletoescapefromthebinding
cavity due to steric hindrances. However, the crosslinking
insulin is ‘allowed’ to dissociate indirectly, for example, as
follows: r1 234-r1 23-r13-r3 (see Figure 2), leading to
dissociation of the insulin molecule, which was initially
crosslinking sites 1 and 2 in r1 234.
Modelling the ligand dependence of the receptor dissocia-
tion rate requires explicit consideration of the binding of two
types of ligand: unlabelled (‘cold’) and radioactively labelled
(‘hot’), which leads to the formation of 77 distinct receptor
intermediaries. The number of intermediaries can be reduced
to 35 if the initial conditions of the used experimental set-up
are imposed. Mathematical modelling of the interactions
between these 35 intermediaries (employing a system of the
corresponding 35 differential equations) is described in the
Supplementary information.
Modelling the IGF1 receptor binding kinetics
The IGF1 receptor kinetics can be modelled in essentially the
same way as described for the insulin receptor except that (1)
the third IGF1 molecule (as justiﬁed before) is not ‘allowed’ to
bind to the receptor and (2) IGF1 does not dimerize
(Brzozowski et al, 2002).
Insulin receptor as a harmonic oscillator
VV Kiselyov et al
& 2009 EMBO and Macmillan Publishers Limited Molecular Systems Biology 2009 7Experimental data used for modelling
Two sets of data were used for modelling. In the ﬁrst one
(a competition experiment), IM9 and 293 EBN cells were
incubated for 2.5h with hot insulin and 4h with hot IGF1,
respectively, in the presence of various concentrations of the
respective cold ligand. Concentration of the hot ligand was 7pM
in both cases. Thereafter, the amount of bound radioactivity was
measured (Figure 5A and B). In the second set (quantiﬁcation of
theliganddependenceofthedissociationrate),IM9and293EBN
cells were pre-incubated for 2h with 24pM hot insulin and IGF1,
respectively. Thereafter, the hot ligand was removed and cells
were incubated in a 40-fold dilution for various periods of time
with various concentrations of the respective cold ligand (De
Meyts et al, 1973). The amount of the remaining pre-bound
radioactivity was then measured (Figure 5C and D). To minimize
the effect of receptor recycling on the apparent kinetics, the data
wereobtainedat151C.Therecyclingrateat151Cisexpectedtobe
reduced 50- to 100-fold compared with that at 371C. The reduced
rate is still too high to be totally ignored because of long
incubation times (up to 4h). Modelling receptor recycling is
described in the Supplementary information.
Fitting of the insulin receptor model to the
experimental data
Fitting of the insulin receptor kinetics was carried out in
Mathematica 5.2 (Wolfram Research, 2005) using a genetic
algorithm (Mitchell, 1996) (with random initial values of all of
the parameters) in combination with gradient minimization
(see Supplementary information). The ﬁtting procedure was
repeated 25 times (every time with a different set of randomly
selected initial parameters) and the averagevalues of the ﬁtted
parameters and their standard deviations are shown in Table I.
As appears from Table I, the genetic algorithm converges to
very similar solutions, regardless of the initial choice of
parameters,whichindicatesthatalloftheusedparameterscan
be identiﬁed uniquely. As can be seen from Figure 5A and C,
there is a very good ﬁt between the simulated and experi-
mental data points for the competition experiment (Figure 5A)
(shownalsoasaScatchardplotinFigure5A)andfortheligand
dependence of the dissociation rate (Figure 5C), which reﬂects
the fact that on average the simulated data points are within
±0.53 standard deviations from the experimental data points.
Ifonedoesnot assumethat d1
0¼d1andd2
0¼d2,then thebestﬁt
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Figure 5 Fitting of the model to the experimental data for the insulin/IGF1 binding. (A, B) Competition experiments for the insulin and IGF1 binding, respectively
(shown also as Scatchard plots in the insets). (C, D) Percentages of hot insulin and IGF1, respectively, remaining after dissociation for 20 and 60min in the presence of
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0 and d2
0 are approximately three times
greater than d1 and d2, respectively. However, the ﬁt is
improved only marginally, and the values of the other
parameters are not changed signiﬁcantly, which means that
for practical purposes the assumption that d1
0¼d1 and d2
0¼d2
is reasonable. The Kd values for the two sites are approxi-
mately 6.4 and 400nM. As the experimentally determined Kd
for site 1 is approximately 10nM, and for site 2 in the sub-
micromolar range (Scha ¨ffer, 1994), it is reasonable to assign
the6.4nMKdtosite1,andthe400nMKdtosite2.Crosslinking
of sites 1 and 2 leads to an apparent high-afﬁnity binding with
a 0.19nM Kd (determined from the initial slope of the
simulated Scatchard plot), which is in good agreement with
the experimentally determined value for these cells (approxi-
mately 0.2nM). It is obvious that simulation of insulin binding
to the monomeric insulin receptor would result in approxi-
mately 34-fold (6.41/0.19) reduction of the apparent afﬁnity
(in good agreement with a 30-fold reduction observed
experimentally), and the monomeric form would show no
liganddependenceforthedissociationrate(alsoinaccordance
with the experiments). However, the simulated Scatchard plot
of the monomeric receptor would be curvilinear (because sites
1 and 2 have different afﬁnity), whereas the experimental one
seemstobelinear(DeMeyts,1994).Itshouldbenotedthatsite
2 consists ofresidueslocated in threeinsulin receptordomains
(L2,F n 1 and Fn2) and disruption of the insulin receptor
quaternary structure (due to reduction of the covalent S–S
bonds, necessary for production of the monomeric form) is
quite likely to disrupt this site.
Fitting of the IGF1 receptor model to the
experimental data
Initial ﬁtting of the IGF1 receptor kinetics in the same way as
fortheinsulinreceptorproducedagooddataﬁt,butconverged
to similar solutions only for the a1 and d1 parameters (data not
shown). It should be noted that the a2 and d2 parametersin the
insulin receptor ﬁtting are constrained by the upturn of the
curve for the ligand dependence of the receptor dissociation
rate (see Figure 5C), which happens at insulin concentrations
of higher than 100nM (this corresponds to binding of the third
insulin molecule at site 2 with 400nM Kd). However, this
upturn is absent in the curve for the IGF1 receptor (see
Figure 5D), and as a result, the site 2 parameters are not
constrained sufﬁciently to produce a unique determination
from the binding data alone.
To estimate the site 2 parameters, we made an assumption
that the crosslinking constant, kcr, of the IGF1 receptor is
similar to that of the insulin receptor. The plausibility of this
assumption is based on the fact that kcr depends on the
dynamics of the large-scale collective motions in the receptor,
which are essentially determined by the macromolecule’s
global topology and are insensitive to structural details (for
review, see Bahar and Rader, 2005). The structure of the IGF1
receptor dimer has not yet been determined, but the structure
of the IGF1 receptor L1-CR-L2 fragment is very similar to the
equivalent insulin receptor fragment (Lou et al, 2006). Taking
also into account high sequence similarity between the two
receptors and the fact that the hybrid insulin–IGF1 receptors
bind IGF-I with high afﬁnity, there is no doubt that the global
topology of the two receptors is very similar. Thus, the
assumption that the crosslinking constants of the two
receptors are similar is quite reasonable.
Fitting data with the ﬁxed kcr parameter (equal to the kcr for
the insulin receptor) results in similar solutions regardless of
the initial choice of the other parameters (see Table I) and a
good data ﬁt (see Figure 5B and D). The only parameter that is
not well deﬁned is a2. Compared with the insulin receptor, the
IGF1 receptor appears to have 1.6 higher apparent afﬁnity, but
slower association and dissociation kinetics: a1 is lower 1.4-
fold, d1 is unchanged, a2 appears to be lower 3.2-fold (but this
result is not very reliable due to a large uncertainty in a2) and
d2 is lower 2.4-fold. Acomparison in the ligand dependence of
the receptor dissociation for the insulin and IGF1 receptors,
based on the estimated parameter values (see Table I), is
shown in Figure 5E and F.
Discussion
In this article, we present the ﬁrst mathematical model that
accurately reproduces all the kinetic properties of the insulin
and IGF1 receptors. In previous models of the insulin receptor
binding kinetics (kinetics of the IGF1 receptor has not been
modelled before) (Hammond et al, 1997; Wanant and Quon,
2000; Sedaghat et al, 2002), a two-site binding model wasused
to generate a curvilinear Scatchard plot resembling that of the
insulin receptor, but modelling of the ligand dependence of the
dissociation rate was not even attempted. Our model is
different from the previous ones not only because it is capable
of accurately reproducing all the kinetic properties of the
insulin and IGF1 receptors but also because it is the ﬁrst model
that gives a physically plausible description of the two
receptors’ binding and activation in terms of interactions
between the molecular components and takes fully into
account the combinatorial complexity arising from multi-
valent binding to multiple receptor conformations.
The presented mathematical model builds on a structurally
and thermodynamically justiﬁed assumption that the insulin
receptor conformational change (required for the receptor
activation) can be described by harmonic oscillations of the
receptorsubunits.Byanalysis of thebehaviourof an ensemble
of the insulin receptor ‘harmonic oscillators’ in thermal
equilibrium with the surrounding milieu, we developed a
physically plausible model of the receptor crosslinking
(activation), which allows to model the latter in a simple
Table I Fitted parameter values for the insulin and IGF1 receptor kinetics
Parameters Insulin kinetics IGF1 kinetics
Apparent Kd (nM) 0.19±0.005 0.12±0.006
Kcr (s
 1) 0.33±0.099 0.33
Site 1 Kd (nM) 6.41±0.78 9.09±0.40
Site 2 Kd (nM) 399±76 490±460
a1 (s
 1M
 1) 490000±26000 347000±7600
d1 (s
 1) 0.0031±0.00031 0.0032±0.000091
a2 (s
 1M
 1) 27900±12100 8700±8200
d2 (s
 1) 0.010±0.0024 0.0042±0.00014
Endocytosis rate (% per h) 12.1±3.2 20.6±0.1
Exocytosis rate (% per h) 8.3±12.1 0.2±0.3
Insulin receptor as a harmonic oscillator
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binding to two different sites requires four parameters, the
harmonic oscillator model requires only ﬁve parameters. In
spite of this, the model gives a very accurate description of the
insulin receptor binding kinetics, and with a minor modiﬁca-
tion—of the IGF1 receptor as well.
The presented model uses a rather complex network of
interactions for description of the insulin kinetics. However,
now that the parameters have been determined, this network
may be reduced substantially depending on the experimental
set-up. Simulations show that at physiological concentrations
of the two ligands (i.e. lower than 0.1nM), the kinetic network
shown in Figure 4B simpliﬁes to a very simple scheme, shown
in Figure 6, in which the major route (accounting for 77% at
equilibrium) is shown by solid lines, and the supplementary
(accounting for 23%)—by dashed lines. If the supplementary
routeisignored,theequilibriumlevelofr1 2canbecalculated
as follows:
r1 2 ¼
rtotkcr=ðkcr þ d2Þ
1 þ d2d1
a1ðd2þkcrÞ=L
where L is the insulin concentration and rtot is the total
receptor level. By comparing this expression with the formula
for a single site binding:
bound ¼
rtot
1 þ Kd=L
we obtain that the insulin receptor Kd can be calculated from
the values of the individual parameters as
Kd ¼
d1d2
a1ðd2 þ kcrÞ
Using the determined parameter values (see Table I), we
obtain from this formula that the insulin receptor Kd can be
estimated as 0.186nM (in good agreement with experiments).
The scheme shown in Figure 6 is also valid for the
physiological concentrations of IGF1, and applying the above
formula to the estimated IGF1 parameters (see Table I), the
IGF1 receptor Kd can be estimated as 0.114nM (also in good
agreement with experiments).
Our model represents an essential ﬁrst step in building a
systems biology analysis of the insulin/IGF-I signalling networks
to explain the combinatorial nature of their biological speciﬁcity.
It has been demonstrated previously that mitogenic potencies of
insulin analogues with altered kinetic properties correlate well
withtheanalogues’dissociationratefromthereceptor:theslower
the dissociation, the higher the mitogenic potency (Shymko et al,
1997; Kurtzhals et al, 2000). In this study, we have shown that
IGF1 dissociates from its receptor much slower than insulin
(compare dissociations shown in Figure 5C with D at physiolo-
g i c a lc o n c e n t r a t i o n so ft h et w ol i g a n d s ,i . e .b e l o w0 . 1n M ) .T h e
apparentdissociationratesforIGF1andinsulin(inthepresenceof
the two ligands at physiological concentrations) can be estimated
from Figure 5C and D as 0.16 and 0.54h
 1, respectively. Thus,
IGF1 also complies with the above-mentioned correlation of
mitogenicity versus dissociation rate, as IGF1 dissociates slower
and it is more mitogenic than insulin. This suggests that kinetic
proofreading could be one of the factors determining the
signalling speciﬁcity of insulin, IGF1 and the insulin analogues
(at least as far as mitogenicity is concerned). In the kinetic
proofreading model of signalling speciﬁcity (McKeithan, 1995;
Hlavacek et al, 2001), the activated receptor must complete a
cascade of reversible modiﬁcations before a cellular response can
occur. If the ligand dissociates before the full set of modiﬁcations
is complete, the receptor reverts to its basal unmodiﬁed state.
Thus, the average lifetime of the receptor in the activated state
(which is equal to the reciprocal of the ligand dissociation rate
constant) determines whether or not a particular biological
responseoccursinasignallingcascadethatisunderastrictkinetic
proofreading control. However, application of the kinetic proof-
reading concept to the insulin/IGF1 signalling appears to be
problematic, because the average lifetime of the insulin and IGF1
receptors in the ligand-bound state is approximately 2 and 6h
(calculatedfromtherateconstantsestimatedabove),respectively,
whereas all of the insulin/IGF1 receptor effectors require at most
20minformaximumactivationinbrownadipocytes(Kru ¨geretal,
2007) and 45min in white adipocytes (Schmelzle et al, 2006),
withthemajorityoftheeffectorsrequiringonlyfrom1to5minfor
the maximum activation.
However, according to the presented model, the active state
is maintained continuously for a much shorter period of
time than the ligand-bound state. If we consider an insulin
receptor intermediary with one insulin molecule bound
(which corresponds to the binding under physiological insulin
concentrations),thentheinsulinreceptormoleculeisexpected
to shuttle between the active r1 2 state and the inactive r1 and
r2 states (see Figure 6). On the basis of the determined rate
constants (see Table I), it is easy to calculate that the insulin
receptor is expected to be continuously in the active state on
average for approximately 76s, whereas the IGF1 receptor for
approximately 135s. Thus, the difference in the average
lifetime of the activated states of the two receptors is
approximately two-fold. This two-fold difference, as demon-
strated by Hlavacek et al (2001), can result in high signalling
speciﬁcity depending on the kinetic parameters of a particular
signalling pathway. As the majority of the insulin/IGF1
receptor’s effectors reach maximum activation with a delay
of 1–5min after stimulation with the ligand (Kru ¨ger et al,
2007), the predicted lifetimes of the active states of the two
receptors are sufﬁciently short to have a potential effect on
some of the effectors due to kinetic proofreading. Whether or
not a particular effector is under control of kinetic proof-
reading requires a careful kinetic analysis of the signalling
pathwayinvolved,whichisnottheaimofthisstudy.However,
it is interesting to note that activation of the Ras–MAP kinase
pathway, responsible for the control of cell growth, results in a
maximum activation of the ERK1 and ERK2 kinases with a
delay of approximately 5min (Kru ¨ger et al, 2007). If we
hypothesize that this pathway is under control of kinetic
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Figure 6 Scheme of the insulin receptor binding at physiological insulin
concentrations.
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the time period necessary for activation of the two MAP
kinases, then IGF1 is expected to activate this pathway more
efﬁciently than insulin, as the average lifetime of the activated
state of the IGF1 receptor is two-fold smaller than the time
period required for the MAP kinase activation, whereas in the
case of the insulin receptor it is four-fold smaller. The above
observation provides a possible explanation for the fact that
IGF1 is more mitogenic than insulin, and in general for the
correlation between the mitogenicity of insulin analogues and
the kinetics of their dissociation. Whether or not it is true
requires further investigation.
The soluble insulin receptor has a 10-fold higher afﬁnity
than the receptor expressed in the cell membrane (Scha ¨ffer,
1994). The reason for this interesting phenomenon has until
now been lacking. However, the presented model provides a
naturalexplanationforit.Asdiscussedbefore,thecrosslinking
constant depends on the dynamics of the receptor conforma-
tional change. As the conformational change is coupled with
some movement of the receptor transmembrane subunits in
the membrane, the dynamics in solution are expected to be
faster due to lower viscosity of the buffer solution (used in the
binding experiments) in comparison with the cell membrane.
The faster dynamics are expected to result in a larger value for
the crosslinking constant, and thus higher afﬁnity. For more
discussion of this topic as well as an analysis of the receptor
dissociation routes leading to the ligand dependence of the
receptor dissociation, see Supplementary information.
It should be pointed out that the scope of our model is far
from being purely theoretical. It has in fact wide-ranging
applications due to its ability to provide robust determination
of experimental binding parameters. Thus, we have now
evaluated the ﬁve constants that deﬁne the model for the two
alternatively spliced isoforms of the insulin receptor and
solved some kinetic issues that had been controversial for
many years (Knudsen et al, manuscript in preparation). We
have shown that the insulin receptor A isoform (lacking exon
11) has 1.5-fold higher afﬁnity and slightly faster apparent
association and dissociation kinetics compared with the
insulin receptor B isoform (containing exon 11). The differ-
ences between the two isoforms appear to be entirely due to
the parameters of the site 1: the a1 and d1 are larger three- and
two-fold, respectively, in the A isoform compared with the
B-isoform. We have also started a detailed evaluation of the
kinetics of binding of a number of ‘supermitogenic’ insulin
analogues to both insulin receptor isoforms, to determine
which parameters correlate with enhanced mitogenicity. This
is a critical issue in the molecular toxicology of insulin
analogues, which are increasingly replacing regular insulin in
the therapy of diabetes mellitus; enhanced mitogenicity in
vitro of some analogues has been an issue of great concern
(Kurtzhals et al, 2000; Hansen, 2008).
In conclusion, we present the ﬁrst model that allows to
explain mathematically all the kinetic properties of the insulin
andIGF1receptors.ThemodelmaybeadaptabletootherRTKs
as well as cytokine receptors. Also, there is growing evidence
that many receptors of the GPCR family (containing more than
800 members in humans) function as pre-bound dimers, and
some of them have been shown to display negative coopera-
tivity in ligand binding similar to that of the insulin receptor/
IGF1R (Springael et al, 2007). The present model may thus be
used for modelling not only the insulin and IGF1 receptors’
binding but also a large number of other receptors in which
ligand crosslinking occurs.
Supplementary information
Supplementary information is available at the Molecular
Systems Biology website (www.nature.com/msb).
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